uniQure Stock Rises Pre-Market After Investigational Huntington’s Disease Drug Slows Disease In Trial

The company stated that high-dose AMT-130 demonstrated 75% disease slowing at 36 months, as measured by the composite Unified Huntington's Disease Rating Scale.
Global stock market chart and trading board - stock photo
Representative image of stock market chart on a glowing particle world map and trading board. (Photo by Yuichiro Chino/Getty Images)
Profile Image
Anan Ashraf·Stocktwits
Updated Sep 24, 2025 | 7:44 AM GMT-04
Share this article

uniQure N.V. (QURE) on Wednesday said that a high dose of its experimental drug AMT-130 demonstrated a statistically significant slowing of disease progression in Huntington’s disease in an early-to-mid stage trial.

Huntington’s disease is a rare, inherited neurodegenerative disorder that leads to motor symptoms including chorea, behavioral abnormalities, and cognitive decline. The company stated that high-dose AMT-130 demonstrated 75% disease slowing at 36 months, as measured by the composite Unified Huntington's Disease Rating Scale (cUHDRS), a comprehensive assessment tool used in clinical trials for Huntington's disease.

Shares of the company rose 3% in the pre-market session at the time of writing. 

Get updates to this developing story directly on Stocktwits.

Subscribe to Trends with No Friends
All Newsletters
High Relative Strength, Low Social Following
Read about our editorial guidelines and ethics policy